Shares of ViroPharma (VPHM -6.3%) slump after the company releases results of its Phase 2 trial...

|By:, SA News Editor

Shares of ViroPharma (VPHM -6.3%) slump after the company releases results of its Phase 2 trial of its Cinryze treatment for angioedema in combination with Halozyme’s Enhaze drug delivery platform. Stifel Nicolaus says the data validates utilization, but warns logistical issues may pop up related to manufacturing capacity and cost before a twice-a-week dosing is a feasible option.